Target- |
Mechanism- |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
Efficacy and Safety Phase IIb Study of Recombinant Human Serum Albumin/ Granulocyte Colony-Stimulating Factor Fusion Protein for Injection to Prevent Neutrophilic Granulocytopenia Among Chemotherapy Breast Cancer Patients
Evaluation of the efficacy and safety of recombinant human serum albumin / granulocyte-stimulating factor fusion protein for injection to prevent chemotherapy-induced neutropenia
rHSA/GCSF预防化疗引起的中性粒细胞减少症的有效性和安全性Ⅱb期临床研究
[Translation] Phase Ⅱb clinical study on the efficacy and safety of rHSA/GCSF in preventing chemotherapy-induced neutropenia
评价注射用重组人血清白蛋白/粒细胞刺激因子融合蛋白预防化疗引起的中性粒细胞减少症的有效性和安全性,为Ⅲ期临床试验安全和有效的给药方案提供依据。
[Translation] To evaluate the efficacy and safety of recombinant human serum albumin/granulocyte stimulating factor fusion protein for injection in preventing chemotherapy-induced neutropenia and to provide a basis for safe and effective dosing regimens in phase III clinical trials.
Evaluate the Pharmacokinetic and Pharmacodynamic Profile, Safety, and Tolerability of Escalating Single Dose & Multiple Dose by Using Recombinant Human Serum Albumin/Interferon alpha2b Fusion Protein in Hepatitits B Patients
The purpose of this study is to evaluate the dosages of recombinant human serum albumin/interferon alpha2b fusion protein injection on HBV subjects. The secondary purposes is to get the PK/PD data in recombinant human serum albumin/interferon alpha2b fusion protein injection on HBV subjects.
100 Clinical Results associated with Tianjin PuYing Biotechnology Co., Ltd.
0 Patents (Medical) associated with Tianjin PuYing Biotechnology Co., Ltd.
100 Deals associated with Tianjin PuYing Biotechnology Co., Ltd.
100 Translational Medicine associated with Tianjin PuYing Biotechnology Co., Ltd.